Objective: To observe the effect of Kushen injection combined with GP regimen on the clinical effect

quality of life and immune function of patients with non-small cell lung cancer. Method: From January 2013 to December 2014

120 cases of non small lung cancer patients treated by respiratory department of internal medicine were selected. The patients were randomly divided into control group and experiment group with random number table method. Control group (gemcitabine+cisplatin) received GP regimen chemotherapy. Injection of gemcitabine was dissolved in 250 mL normal saline at a proportion of 1000 mg·m-3on day 1 and day 8 respectively

with intravenous drip for 30 min. Cisplatinswas was administered by intravenous drip at 25 mg·m-3 on day 2

day 3 and day 4.In the experimental group

compound Kushen injection was also used in addition to GP regimen

20 mL

once a day

for continuous 10 days

and with 21 days as 1 cycle. After 2 cycles

short-term curative effect

life quality and immune function were compared between two groups. Result: In the experimental group

the total effective rate was 75.0%

higher than 56.67% in control group

with statistically significant difference (P<0.05). The effective rate of life quality in the experimental group was higher than that of the control group. CD3+

CD4+

CD4+/CD8+levels in the control group were lower than those before treatment

while CD3+

CD4+

CD4+/CD8+levels in the experimental group were hihjer than those before treatment

with statistically significant difference (P<0.05). The change of NK cells before and after treatment was not statistically significant in two groups. IgG

IgM

IgA in patients in the control group were lower than those

before treatment

while immunoglobulin in the experimental group were higher than those before treatment

with statistically significant difference (P<0.05). Conclusion: Kushen injection combined with GP regimen has clear clinical efficacy for patients with non-small cell lung cancer. It can improve the quality of life and improve their immunity

for patients with lung cancer. It is worthy of clinical application.